CLIA MxA

Chemiluminescence kit for the detection of MxA in human whole blood.

Coming soon
Catalog Number: CL-MxA050
Size: 50 tests
Regulatory status: CE IVD
Clinical topic: Sepsis & Inflammation
Diagnostic panel: COVID-19
Respiratory Diseases
SIRS, Sepsis, and Severe Viral Infection
CLIA MxA
  • Determination of MxA (Myxovirus protein A) concentration in human whole blood samples
  • Identification and monitoring upper respiratory virus infection in neonates and infants, and post-surgery patients
  • Monitoring of Interferon therapy effectiveness in multiple sclerosis and Sjögren's syndrome patients

MxA plays a key role in host defense against viral infection by acting directly on viral particles (RNA, DNA) in the cell and is involved in the activation of the endoplasmic reticulum. Elevated blood MxA levels are due to the presence of viruses in the body or increased concentrations of IFN I (IFN-α and IFN-β). Thus, it is a specific marker of viral infection as a counterpart to PCT in bacterial infections.

Measurement of MxA is suitable for the confirmation of respiratory diseases (Rotavirus, rhinovirus, respiratory syncytial virus, parainfluenza and influenza virus, metapneumovirus), but also in connection with COVID-19.

The use of therapeutic IFN-beta is associated with the development of neutralizing antibodies (NAbs). NAbs inactivate IFN-beta in 5-10 % of patients. Determination of MxA levels is recommended to monitor the effectiveness of treatment with Interferon (IFN-α and IFN-β) in patients with multiple sclerosis, Sjögren's syndrome, and in women with HCV planning to become pregnant. The decrease of the MxA levels indicates the need to modify the therapy used.

Technical specifications

Technical data
References
Related Products

Technical data

Assay time21 min
Assay stability (on board)30 days
Sample matrix whole blood lysate (EDTA collection tube)
Sample volume40 µL
Sample stability3 days at RT, 7 days at 2-8 °C, 24 months at -20 °C
Concentration range0 – 40 ng/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions
Note

Lysing buffer non included

References

References to CLIA MxA

  • Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008 Jul;8(7):559-68. doi: 10.1038/nri2314. PMID: 18575461; PMCID: PMC2522268.
    See more on PubMed
  • Numajiri Haruki A, Naito T, Nishie T, Saito S, Nagata K. Interferon-inducible antiviral protein MxA enhances cell death triggered by endoplasmic reticulum stress. J Interferon Cytokine Res. 2011 Nov;31(11):847-56. doi: 10.1089/jir.2010.0132. Epub 2011 Oct 12. PMID: 21992152.
    See more on PubMed
  • Chieux V, Hober D, Harvey J, Lion G, Lucidarme D, Forzy G, Duhamel M, Cousin J, Ducoulombier H, Wattré P. The MxA protein levels in whole blood lysates of patients with various viral infections. J Virol Methods. 1998 Feb;70(2):183-91. doi: 10.1016/s0166-0934(97)00177-8. PMID: 9562412.
    See more on PubMed
  • Kawamura M, Kusano A, Furuya A, Hanai N, Tanigaki H, Tomita A, Horiguchi A, Nagata K, Itazawa T, Adachi Y, Okabe Y, Miyawaki T, Kohno H. New sandwich-type enzyme-linked immunosorbent assay for human MxA protein in a whole blood using monoclonal antibodies against GTP-binding domain for recognition of viral infection. J Clin Lab Anal. 2012 May;26(3):174-83. doi: 10.1002/jcla.21507. PMID: 22628233; PMCID: PMC6807620.
    See more on PubMed
  • Zav'yalov VP, Hämäläinen-Laanaya H, Korpela TK, Wahlroos T. Interferon- Inducible Myxovirus Resistance Proteins: Potential Biomarkers for Differentiating Viral from Bacterial Infections. Clin Chem. 2019 Jun;65(6):739-750. doi: 10.1373/clinchem.2018.292391. Epub 2018 Dec 28. PMID: 30593466; PMCID: PMC7108468.
    See more on PubMed
  • Haller O, Gao S, von der Malsburg A, Daumke O, Kochs G. Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity. J Biol Chem. 2010 Sep 10;285(37):28419-24. doi: 10.1074/jbc.R110.145839. Epub 2010 Jun 10. PMID: 20538602; PMCID: PMC2937866.
    See more on PubMed
  • Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res. 2011 Jan;31(1):79-87. doi: 10.1089/jir.2010.0076. Epub 2010 Dec 19. PMID: 21166595.
    See more on PubMed
  • Pulia MS, O'Brien TP, Hou PC, Schuman A, Sambursky R. Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic. Ann Med. 2020 Aug;52(5):207-214. doi: 10.1080/07853890.2020.1763449. Epub 2020 May 14. PMID: 32370561; PMCID: PMC7877955.
    See more on PubMed
  • Clark TW, Brendish NJ, Poole S, Naidu VV, Mansbridge C, Norton N, Wheeler H, Presland L, Ewings S. Diagnostic accuracy of the FebriDx host response point-of- care test in patients hospitalised with suspected COVID-19. J Infect. 2020 Oct;81(4):607-613. doi: 10.1016/j.jinf.2020.06.051. Epub 2020 Jun 21. PMID: 32579983; PMCID: PMC7306108.
    See more on PubMed
  • Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, Malucchi S; Italian Multiple Sclerosis Study group. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurol Sci. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Epub 2013 Dec 29. Erratum in: Neurol Sci. 2014 Oct;35(10):1645-6. Troiano, Maria [corrected to Trojano, Maria]. PMID: 24374787.
    See more on PubMed
  • Serana F, Imberti L, Amato MP, Comi G, Gasperini C, Ghezzi A, Martinelli V, Provinciali L, Rottoli MR, Sotgiu S, Stecchi S, Vecchio M, Zaffaroni M, Cordioli C, Capra R. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. PLoS One. 2014 Apr 14;9(4):e94794. doi: 10.1371/journal.pone.0094794. PMID: 24733382; PMCID: PMC3986392.
    See more on PubMed
  • Capra R, Sottini A, Cordioli C, Serana F, Chiarini M, Caimi L, Padovani A, Bergamaschi R, Imberti L. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol. 2007 Sep;189(1-2):102-10. doi: 10.1016/j.jneuroim.2007.06.006. Epub 2007 Jul 9. PMID: 17619058.
    See more on PubMed
  • Matas E, Bau L, Martínez-Iniesta M, Romero-Pinel L, Mañé-Martínez MA, Martínez-Yélamos S. Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients. J Neurol. 2016 Apr;263(4):722-9. doi: 10.1007/s00415-016-8053-z. Epub 2016 Feb 12. PMID: 26872667.
    See more on PubMed

Do you want to learn more?
We're here for you

Please fill in
all fields
marked *
Up
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.
Agree